JPH10191862A - Drug volatilization - Google Patents

Abstract

PROBLEM TO BE SOLVED: To volatilize a volatile drug in air by putting a granular drug soaking object into a vessel, blowing air from a fan to this vessel and stirring this drug soaking object with the force of the wind. SOLUTION: A drug cartridge covering the upside and downside of cylinder having an inner diameter of 8cm and a height of 10cm with a net is provided on the bellowing port side of a DC brushless axial current fan motor in 8cm square, for example, and a granular drug soaking object of 2g with a diameter of 2mm soaking prallethrin of 300mg is put into this cartridge. Then, when this device is repeated 30 times at the integrals of drive for 12 hours and stop for 12 hours, its economical volatilization quantity is stabilized for a long time as shown in the figure.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for volatilizing chemicals, in which volatile chemicals are volatilized in the air by using the wind power of a fan.

[0002]

2. Description of the Related Art As a method of volatilizing and releasing volatile chemicals into the air by the wind of a fan, a wind from a fan is applied to an impregnated body that retains the chemicals and has an appropriate air permeability. The one that was applied is the actual opening 61-1822
Japanese Unexamined Patent Publication No. Hei 7-11850 discloses a definition of the relationship between the wind power and the air permeability of a fan in Japanese Patent Publication No. 73-73.

[0003] The drug-impregnated bodies in these conventional techniques are:
All of them are solidified into a single piece. Therefore, this is an effective means when the impregnated drug is a drug with a high vapor pressure and easy to volatilize. In the case of volatilizing a chemical agent or volatilizing a large amount of a drug at a time, the following measures are required.

That is, (1) the volatilization area of the drug-impregnated body is increased. (2) Enlarge the voids in the drug-impregnated body to promote the passage of wind. (3) Enhance the output of the fan, and so on.

[0005]

When each of the above measures is implemented, the overall volume of the chemical impregnated body increases, and the size of the fan increases, resulting in poor energy efficiency. In particular, the increase in the volume of the drug-impregnated body causes the following problems.

[0005] (1) As the distance from each part of the drug-impregnated body, particularly from the air outlet, increases, the air volume per unit time decreases due to the air resistance of the drug-impregnated body. If the flow direction is large,
A partial difference occurs in the wind power instantaneously received by the drug-impregnated body, which leads to a deviation in the amount of volatilization from each part of the drug-impregnated body, and hinders stable drug volatilization.

(2) Even in the case of the above (1), if the impregnated drug is quickly homogenized, stable volatilization is possible even in a solid form of the drug impregnated body. However, as the size of the drug-impregnated body increases, the moving distance of the drug increases, and a longer time is required for uniformity.

(3) The increase in size of the drug-impregnated body is caused by the above (1)
The exhaust port of the impregnated container due to the problems described in (1)
From the air per unit time, which leads to a decrease in the ability of the drug to volatilize into the room, that is, a decrease in the efficacy of the drug. In addition, increasing the wind power of fans to solve this is a waste of energy, inefficient, and economically disadvantageous.

[0008]

The present inventors have made intensive studies to solve the above-mentioned problems, and as a result, have found solutions to each of the problems.

That is, as a means for solving the problem (1), the medicine impregnated body is granulated, and the medicine impregnated body itself is agitated, so that the amount of air received by each medicine impregnated body is made uniform. As a result, it is possible to eliminate the variation of the medicine impregnated body depending on the position in the flow direction of the wind. The test methods and test results to prove this are shown below.

[0010] A test device was provided by providing an impregnated container having a tube with an inner diameter of 8 cm and a height of 10 cm above and below a cylinder at the outlet of a fan having a wind outlet of 8 cm square. 2 g of a granular drug-impregnated body having a diameter of 4 mm and impregnated with 300 mg of the drug was charged therein, and a partial variation of the amount of the remaining drug after driving for 3 days continuously for 24 hours was measured.

[0011] In addition, a partial variation in the amount of residual medicine was measured using an apparatus in which a honeycomb-shaped integral fixed-type medicine-impregnated body was placed on the outlet side of the same 8 cm square fan as the object. The results are shown in Table 1.

[0012]

[Table 1]

The numerical values in the table indicate the residual ratio of the drug when the charged amount of the drug is 100. The measurement site indicates the distance from the outlet of the fan in the medicine-impregnated body.

[0014] In the case of using an integral fixed type drug-impregnated body,
The portion near the outlet of the fan volatilizes well, and the far portion hardly volatilizes, and 90% or more of the drug remains. On the other hand, when the granular drug-impregnated product was used, the drug-impregnated product was volatilized while the drug-impregnated product was constantly stirred, so that a result with little difference in partial residual amount was obtained.

Further, the following research was conducted as a means for solving the problem (2). In other words, by granulating the drug-impregnated bodies and increasing the number thereof, each drug-impregnated body becomes smaller, and the transfer distance of the drug becomes shorter. As a result, with the volatilization of the drug from the surface of the drug-impregnated body, the replenishment of the drug from the center (uniformity of the drug concentration) was quickly performed, and the stable volatilization of the drug became possible. Further, a method of adding various solvents may be considered as a means for promoting uniformity of the drug in each impregnated body. This is an effective means when using a drug having a high viscosity and a low transfer rate.

Table 2 and FIG. 1 show the results of a study on the volatilization pattern of a drug when a granular drug-impregnated product and an integrated fixed-type drug-impregnated product were used using the same test apparatus as described above. Each drug impregnated body is impregnated with the same type and the same amount of drug, and the amount of volatilization per unit time when driven continuously for 15 days is the remaining amount of drug on the fifth, tenth, and fifteenth days from the start. Estimated from

[0017]

[Table 2]

As a result, the amount of volatilization of the one-piece fixed type drug-impregnated body shows a tendency to decrease almost proportionally from the start of driving, whereas the case of the granulated drug-impregnated body has a stable volatilization amount. I keep it. This granulates the drug impregnated body,
By stirring this, the drug concentration of the whole drug impregnated body becomes uniform, and the transfer of the drug in each drug impregnated body is performed, and the drug is volatilized and the weight is reduced. As a result of the lower specific gravity of the drug and the increased momentum of the drug-impregnated body, a constant amount of volatilization can be obtained even when the drug concentration is low. Can be Also, the effective volatilization rate, which is the ratio of the remaining amount on the 15th day to the charged amount of the drug shown in Table 2, indicates that the integrated fixed-type drug-impregnated body had a volume of 7%.
In contrast to 2.58%, in the case of the granular drug-impregnated body, it is 89.46%, which indicates that the drug is volatilized very efficiently.

Further, the following research was conducted as a means for solving the above problem (3). In other words, the wind received by the medicine-impregnated body becomes the wind received from the fan and the wind received when the medicine itself rotates, and the energy is effectively used.
As a result, the total surface area of the drug impregnated body is smaller than that of the conventional one, and the loss of wind power is reduced. Table 3 shows the results of measuring the wind speed at a distance of 5 cm and 10 cm upward from the drug volatilization port when the true volume of each of the granular drug-impregnated body and the integral honeycomb-shaped drug-impregnated body was the same. Show. Also in this test, the granular drug impregnated body showed good results in comparison with the one-piece fixed type drug impregnated body, which proved that the wind speed was high and the wind power loss was small.

[0020]

[Table 3]

From the above tests and the results thereof, the following has been found. That is, in order to eliminate variations due to the location of the drug-impregnated body and to effectively use the wind energy of the fan and maintain a stable volatilization amount for a long time, the drug-impregnated body itself must be appropriately stirred. . For this purpose, the drug impregnated body must satisfy several conditions. The conditions are as follows.

First, there are matters relating to the shape of the drug-impregnated body. The shape of the drug-impregnated body necessary for carrying out the present invention is a shape having a small frictional resistance that leads to a loss of energy during stirring, that is, the maximum area where the drug-impregnated bodies are in contact with each other is １ ／ or less of the total surface area. Preferably, it is three-dimensional. Specifically, a spherical shape having the smallest friction is most preferable.

Second, the conditions required for the drug-impregnated body are such that the drug-impregnated body has an appropriate impregnating ability and volatilizing ability (release ability) of the drug and an ability to promote rapid homogenization in the drug-impregnated body. Is to have. The ability to impregnate the drug depends on the true volume of the drug impregnated body, and the ability to promote volatilization and homogenization depends on the density of the drug impregnated body, that is, the porosity.

The true volume of the drug-impregnated body necessary for carrying out the present invention is determined from the porosity and apparent volume of the drug-impregnated body, and is shown below according to the physical properties such as the vapor pressure and viscosity of the drug used. It may be arbitrarily adjusted within the range. The range is the true volume of this drug impregnated body, that is, [apparent volume ×
(1−porosity / 100)] is 5 × 10 ⁻⁵ per particle.
5 × 10 ⁵ mm ³ , preferably 5 × 10 ^{−3 to} 5 × 10 ³
mm ³ , more preferably 5 × 10 ^{−2 to} 5 × 10 ⁻¹ m
m ³ . The amount of volatilization to be obtained and the duration of the effect may be adjusted by the number of particles of the granular drug-impregnated material to be used and the concentration of the drug impregnated therein.

Third, the specific gravity of the drug-impregnated body used in the present invention is such that the air volume per unit time when this drug passes through the impregnated body container containing the impregnated body is 0.01 to 1.0 m ³ / m.
When in, it is 0.005 to 0.5. However, when a large fan having an air volume per unit time of 1.0 m ³ / min or more is used, it is possible to use even a specific gravity of 0.5 or more.

As a fourth condition, the chemical impregnated body or the impregnated body container or both of them may be subjected to a treatment for preventing or eliminating static electricity.
This is because static electricity can act as a resistance to impede agitation between the drug impregnated bodies or between the drug impregnated body and the impregnated body container.

In view of the above, in the method for volatilizing a drug according to the first aspect of the present invention, a granulated drug-impregnated body is put into an impregnated container, and a wind from a fan is applied to the container to impregnate the drug-impregnated body with a wind. The drug impregnated in the drug-impregnated body was volatilized while stirring.

Further, the method for volatilizing a drug according to the second invention comprises:
The shape of the drug-impregnated body was such that the maximum contact area where the drug-impregnated bodies were in contact with each other was １ ／ of the total area of each drug-impregnated body.

Further, the method for volatilizing a drug according to the third invention comprises:
The true volume of the drug impregnated body, ie, [apparent volume ×
(1−porosity / 100)] is 5 × 10 ⁻⁵ per particle.
The range was 5 × 10 ⁵ mm ³ .

Further, the method for volatilizing a drug according to the fourth invention comprises:
The air volume per unit time passing through the impregnated container is 0.0
When the pressure was 1 to 1.0 m ³ / min, the specific gravity of the granular drug-impregnated body was 0.005 to 0.5.

Further, in the method for vaporizing a drug according to the fifth aspect of the present invention, at least one of the drug-impregnated body and the impregnated body container containing the drug-impregnated body is subjected to a treatment for preventing or eliminating static electricity and then volatilized. To do.

[0032]

Embodiments of the present invention will be described below. Note that the present invention is not limited to the contents described above. In the present invention, various volatile agents can be used as the agent to be impregnated with the granular agent-impregnated body according to the purpose of use.

For example, when used for insect killing,
Various volatile insecticides conventionally used can be used, and examples thereof include pyrethroid insecticides, carbamate insecticides, and organic phosphorus insecticides. In general, pyrethroid insecticides are preferably used because of their high safety, and specific examples thereof include the following. In addition, each example is a general name, a chemical name (trade name,
Manufacturer).

Arlesrin; 3-allyl-2-methylcyclopenta-2-en-4-one-1-yl dl-cis / trans-chrysanthemate. (Pinamine, Sumitomo Chemical Co., Ltd.) dl.d-T80-aresulin; 3-allyl-2-methylcyclopenta-2-en-4-one-1-yl d
-Cis / trans-chrysanthemate. (Pinamine Forte, Sumitomo Chemical Co., Ltd.) dl.dT-aresulin; 3-allyl-2-methylcyclopenta-2-en-4-one-1-yl d-trans-chrysanthemate. (Bioarethrin) d-d-T-aresulin; d-3-allyl-2-methylcyclopenta-2-en-4-one-1-yl d-
Trans-chrysanthemato. (Esviol) d-d-T80-praletrin; d-2-methyl-4
-Oxo-3-propargylcyclopent-2-enyl d-cis / trans-chrysanthemate. (Ethoc, Sumitomo Chemical Co., Ltd.)-Phthalthrin; N- (3,4,5,6-tetrahydrophthalimide) -methyl dl-cis / trans-chrysanthemate. (Neopinamine, Sumitomo Chemical Co., Ltd.) d-T80-phthalthrin; (1,3,4,5,6,6)
7-Hexahydro-1,3-dioxo-2-indolyl) methyl d-cis / trans-chrysanthemate.
(Neopinamine Forte, Sumitomo Chemical Co., Ltd.)-Resmethrin; 5-benzyl-3-furylmethyl d
l-cis / trans-chrysanthemate. (Chryslon, Sumitomo Chemical Co., Ltd.) d-d-T80-resmethrin; 5-benzyl-3-
Furylmethyl d-cis / trans-chrysanthemate. (Chrislon Forte, Sumitomo Chemical Co., Ltd.) Permethrin; 3-phenoxybenzyl dl-cis / trans-2,2-dimethyl-3- (2,2, dichlorovinyl) cyclopropanecarboxylate. (Exmin, Sumitomo Chemical Co., Ltd.) ・ Phenothrin; 3-phenoxybenzyl d-cis /
Trans-chrysanthemato. (Smithulin, Sumitomo Chemical Co., Ltd.) Fenvalerate; α-cyano-3-phenoxybenzyl-2- (4-chlorophenyl) -3-methylbutyrate. (Sumisaidin, Sumitomo Chemical Co., Ltd.) Cypermethrin; α-cyano-3-phenoxybenzyl dl-cis / trans-3- (2,2-dichlorovinyl) -2,2-dimethylcyclopropanecarboxylate. (Agrothrine, Sumitomo Chemical Co., Ltd.) Cyphenothrin; α-cyano-3-phenoxybenzyl d-cis / trans-chrysanthemate. (Gokilate, Sumitomo Chemical Co., Ltd.) Empentrin; 1-ethynyl-2-methylpent-
2-enyl d-cis / trans-chrysanthemate.
(Vaper Surin, Sumitomo Chemical Co., Ltd.) Teralesulin; 2-allyl-3-methyl-2-cyclopenten-1-one-4-yl-2,2,3,3, tetramethyl-cyclopropanecarboxylate. (Knoxulin, Sumitomo Chemical Co., Ltd.) Imiprosulin; 2,4-dioxo-1- (prop-
2-ynyl) imidazolidin-3-ylmethyl (IR)
-Cis / trans-chrysanthemate. (Pral, Sumitomo Chemical Co., Ltd.) Etofenprox; 2- (4-ethoxyphenyl) -2-methylpropyl-3-phenoxybenzyl ether

The following can be exemplified as other drugs (eg, insecticides, repellents, potency enhancers, growth regulators, etc.). · Asetamipurorido; N '- [(6- chloro-3-pyridiyl) methyl] -N ² - cyano -N' methyl acetone Ami diyne. (Mospirane) Diazinon; (2-isopropyl-4-methylpyrimidyl-6) -diethylthiophosphate. (Diazinon) ・ Fenitrothion, MEP; 0,0-dimethyl-0-
(3-Methyl-4-nitrophenyl) thiophosphate. (Sumithion)-pyridafenthion; 0,0-dimethyl-0- (3-
Oxo-2-phenyl-2H-pyridazin-6-yl)
Phosphorothioate. (Offnack) Marathon; dimethyl dicarbethoxyethyl dithiophosphate. (Marathon) ・ Imidaclobride; 1- (6-chloro-3-pyridylmethyl) -N-nitroimidazolidin-2-ylideneamine (hachixan) ・ DDVP; 0,0-dimethyl 0- (2,2-dichloro) vinyl phosphate ・ Benzil Benzoate ・ Isobonyl thiocyanoacetate. (IBTA)-Dehydroacetic acid-Piperonyl butoxide. (P.B.) • Paraoxybenzoic acid • Phenyl salicylate • S-421 • N- (2-ethylhexyl) -bicyclo [2,2,
1] -Hept-5-ene-2,3-dicarboximide. (Sinepirin 222) N, N-diethyl-m-toluamide (diet) pyriproxyfen; 4-phenoxyphenyl (R
S) -2- (2-Pyridyloxy) propyl ether.
(Sumilab)

Next, as the material of the drug-impregnated body usable in the present invention, for example, a porous material molded from an inorganic material such as pulp, viscose, linter, or calcium silicate, or a synthetic fiber such as polypropylene as a raw material is used. Or activated carbon. Above all, plant-derived substances such as pulp, viscose and linter are most preferable as raw materials for the drug-impregnated body in consideration of specific gravity and drug-impregnating ability. Commercially available materials include expanded cellulose beads (trade name: Visco Pearl) manufactured by Rengo Co., Ltd. using pulp and viscose as main raw materials.

As described above, a material having a low specific gravity is preferably used for the drug impregnated body in order to promote quick stirring, and the material of the impregnated body container is non-conductive, lightweight and advantageous in cost. It is preferable to use plastic. However, plastic has a property that the surface is easily charged with static electricity due to contact or friction, and is hard to leak once charged. Therefore, for a drug impregnated body having a low specific gravity, a large resistance is generated at the time of stirring, which may adversely affect energy efficiency. Therefore, it is preferable to perform an antistatic treatment on the drug-impregnated body or impregnated body container of the present invention. Generally, an antistatic treatment method for plastics is widely used as an additive treatment method, and a surfactant is mainly used for this purpose. There are two methods of treatment with an antistatic agent: a method of applying to the surface of plastic (surface coating method) and a method of kneading it into plastic (kneading method). Anionic, cationic, nonionic and amphoteric surfactants, each having its own characteristics, are used. Available. Formulations containing a surfactant as a main component are commercially available from various companies according to each method. For example, “Sunstat AA”, “Sunstat 2012A”, “Sunstat 249” manufactured by Sanyo Chemical Industries, Ltd., and “Colcoat SP-2001” and “Colcoat SP-” manufactured by Colcoat Co., Ltd., which is transparent as a conductive paint. 2002 ".

In the present invention, one or more antioxidants, ultraviolet absorbers, fragrances, deodorants and the like are used in addition to the drugs for the purpose of improving the stability, synergistic effect and adding additional functions. It is possible. When it is desired to more effectively volatilize the difficult-to-evaporate drug, a method of heating the impregnated body container or the fan itself or peripheral members to promote volatilization is also conceivable.

[0039]

Example 1 An 8 cm inner diameter was set on the outlet side of an 8 cm square DC brushless axial fan motor manufactured by Sico Giken Co., Ltd.
A drug cartridge in which the upper and lower sides of a 10 cm-high cylinder were covered with a net was provided, and 2 g of a granular drug-impregnated body (foamed cellulose beads) having a diameter of 2 mm and impregnated with 300 mg of pralethrin was charged therein. FIG. 2 shows the change in the amount of volatilization over time when this device is driven for 12 hours and the interval of 12 hours of rest is repeated 30 times, and the knockdown effect on Culex pipiens at that time is shown in Table 4.
It was shown to. The amount of volatilization at this time is calculated and shown as a value per unit time from the remaining amount of the drug extracted and quantified from the drug-impregnated body at regular intervals, and the efficacy is 2 in a closed space of 8 tatami mats.
The results of the test performed under a constant temperature condition of 5 ° C. are shown.

As shown in FIG. 3, an apparatus for carrying out the first embodiment is provided with a fan motor therein, and a vertically extending outlet (not shown) of the fan motor. Is covered with nets 2a and 2b. In this configuration, when the fan rotates, the wind blows up from the net 2 b on the bottom side of the storage container 3, and the granular drug-impregnated body 4 placed in the impregnated body container 3 flows, during which the drug-impregnated body 4 is moved. Are volatilized and volatilized with the wind from the upper net 2a to the outside.

[0041]

Example 2 1200 mg of arrestin was added to 2 g of foamed cellulose beads having a diameter of 2 mm using the same apparatus as in [Example 1].
2 and Table 4 show changes in the amount of volatilization and knockdown efficacy against Culex pipiens under the same test conditions as in [Example 1].

[0042]

[Example 3] In the same apparatus as in [Example 1], terarethrin was added to 2 g of foamed cellulose beads having a diameter of 4 mm to 1000 m.
g and the effect of knockdown on Culex pipiens under the same test conditions as in [Example 1] are shown in FIG. 2 and Table 4.

[0043]

[Embodiment 4] In the same apparatus as in [Embodiment 1], 2,000 g of empenthrin was added to 2 g of expanded cellulose beads having a diameter of 4 mm.
2 and Table 4 show changes in the amount of volatilization and knockdown efficacy against Culex pipiens under the same test conditions as in [Example 1].

[0044]

[Table 4]

[0045]

As described above, according to the method of the present invention,
It is possible to obtain a long-term stable dispersing action by wind power regardless of the vapor pressure and the target volatilization rate of volatile chemicals that have insecticidal, repellent and growth control functions against various pests. it can.

[Brief description of the drawings]

BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a diagram showing the amount of drug volatilization with respect to the number of days of use of different drug impregnated bodies.

FIG. 2 is a diagram showing the amount of drug volatilized over time of each drug-impregnated body impregnated with different drugs.

FIG. 3 is a perspective view showing an apparatus for volatilizing a drug from a powdery drug-impregnated body.

[Explanation of symbols]

DESCRIPTION OF SYMBOLS 1 ... Body, 2a, 2b ... Net, 3 ... Impregnated container, 4 ...
Drug impregnated body.

Claims (5)

[Claims] 1. A medicine impregnated in a medicine impregnated body is volatilized while the granulated medicine impregnated body is put in an impregnated body container, and a wind from a fan is applied thereto, and the medicine impregnated body is stirred by wind force. A drug volatilization method characterized in that: 2. The shape of the drug-impregnated body is determined by setting the maximum contact area where the drug-impregnated bodies are in contact with each other to １ ／ of the total area of each drug-impregnated body.
The method of claim 1, wherein the method is as follows. 3. The true volume of the drug-impregnated body, that is, [apparent volume × (1−porosity / 100)] is 5 per particle.
Chemical volatilization method of claim 1, wherein the range of ^{× 10 -5 ~5 × 10 5 mm} 3. 4. When the air volume per unit time passing through the impregnated body container is 0.01 to 1.0 m ³ / min, the specific gravity of the granular drug impregnated body is 0.005 to 0.5. The method for volatilizing a drug according to claim 1, characterized in that: 5. A method for preventing generation of static electricity in at least one of a drug-impregnated body and an impregnated-body container for storing the drug-impregnated body.
The method according to claim 1, wherein the vaporization is performed by performing a process for removing the chemical.